Components of placebo effect: Randomised controlled trial in patients with irritable bowel syndrome

BMJ

Volumn 336, Issue 7651, 2008, Pages 999-1003

  Kaptchuk, Ted J ^a   Kelley, John M ^b   Conboy, Lisa A ^a   Davis, Roger B ^c   Kerr, Catherine E ^a   Jacobson, Eric E ^a   Kirsch, Irving ^d   Schyner, Rosa N ^a   Bong, Hyun Nam ^a   Nguyen, Long T ^a   Park, Min ^a   Rivers, Andrea L ^a   McManus, Claire ^a   Kokkotou, Efi ^c   Drossman, Douglas A ^e   Goldman, Peter ^a   Lembo, Anthony J ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ENDICOTT COLLEGE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF HULL   (United Kingdom)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ACUPUNCTURE; ADULT; ARTICLE; ATTENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOCTOR PATIENT RELATION; FEMALE; FOLLOW UP; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PLACEBO EFFECT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS;

ACUPUNCTURE THERAPY; ADULT; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PLACEBO EFFECT; SINGLE-BLIND METHOD; TREATMENT OUTCOME; WAITING LISTS;

EID: 43249121870     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39524.439618.25     Document Type: Article

References (32)

1. Kaptchuk TJ. Powerful placebo: the dark side of the randomized controlled trial. Lancet 1998;351:1722-5.
2. Hrobjartsson A. What are the main methodological problems in the estimation of placebo effects. J Clin Epidemiol 2002;55:430-5.
3. Miller FG, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. J Roy Soc Med 2008 (in press).
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
5. Mitchell CM, Drossman DA.Survey of theAGAmembership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987;92:1282-4.
6. Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:671-82.
7. PatelSM,StasonWB,LegedzaA,OckSM,KaptchukTJ,ConboyL,etal. The placebo effect irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005;17:332-40.
8. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl 2):II43-7.
9. Francis CY, J.Morris J,Whorwell PJ. The irritable bowel severity scoring system: a simplemethod ofmonitoring irritable bowel syndrome and its progress. Alimen Pharmacol Ther 1997;11:395-402.
10. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004;253:666-72.
11. Vanner SJ, Depew WT, Paterson WG, DaCosta LR, Groll AG, Simon JB, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999;94:2912-7.
12. Kaptchuk TJ, StasonWB,DavisRB, LegedzaATR, SchnyerRS, Kerr CE, et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ 2006;332:391-7.
13. Kleinhenz J, Streitberger KJ. Randomised clinical trial comparing the effects of acupuncture and a newly designed placebo needle in rotator cuff tendonitis. Pain 1999;83:235-41.
14. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: longterm prognosis and the physician-patient interaction.Ann InternMed 1995;122:107-12.
15. Chaput de SaintongeM,Herxheimer A.Harnessing the placebo effect in healthcare. Lancet 1994;344:995-8.
16. Keefer L, Blanchard EB. The effects of relaxation responsemeditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study. Behav Res Ther 2001;39:801-11.
17. Drossman DA, Drossman D, Toner BB, Whitehead WE, Diamant NE, Dalton CB, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo formoderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31.
18. Bengtsson M, Ulander K, Borgdal EB, Christensson AC, Ohlsson B. A courseof instruction forwomenwith irritablebowel syndrome.Patient Educ Couns 2006;62:118-25.
19. Lang EV, Benotsch EG, Fick LJ, Lutgendorf S, Berbaum ML, Berbaum KS, et al. Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. Lancet 2000;355:1486-90.
20. Moncher FJ, Prinz FJ. Treatment fidelity inoutcomesstudies. ClinPsych Rev 1991;11:247-66.
21. MangelAW,HahnBA,HeathAT, NorthcuttAR,KongS,Dukes GE, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J IntMed Res 1998;26:76-81.
22. Mangel AW. Personal view: adequate relief as a primary endpoint in irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:879-81.
23. Lembo AL, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-70.
24. Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E. Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci 2003;48:1317-23.
25. DrossmanDA,Patrick DL,WhiteheadWE, Toner BB,DiamantNE,HuY, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999-1007.
26. CamilleriM,NorthcuttAR, KongS,DukesGE,McSorleyD,Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-40.
27. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877-88.
28. CamilleriM,MangelAW,Fehnel SE,DrossmanDA,MayerEA, TalleyNJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007;5:534-40.
29. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med 2002;136:817-25.
30. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. J Neurosci 2005;25:10390-402.
31. Pacheco-López, G, Engler H, NiemiMB, SchedlowskiM. Expectations and associations that heal: immunomodulatory placebo effects and its neurobiology. Brain Behav Immunol 2006:403-446.
32. Allan LG, Siegel S. A signal detection theory analysis of the placebo effect. Eval Health Prof 2002;25:410-20.